Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Up 22.1% in February

Vivos Therapeutics, Inc. (NASDAQ:VVOS) was the recipient of a large increase in short interest in the month of February. As of February 28th, there was short interest totalling 344,000 shares, an increase of 22.1% from the February 13th total of 281,700 shares. Based on an average trading volume of 236,200 shares, the short-interest ratio is presently 1.5 days. Approximately 7.5% of the company’s shares are sold short.

Analysts Set New Price Targets

A number of brokerages have weighed in on VVOS. Alliance Global Partners decreased their price target on Vivos Therapeutics from $8.25 to $6.00 and set a “buy” rating for the company in a report on Tuesday, November 19th. Ascendiant Capital Markets reissued a “buy” rating and set a $6.60 price objective on shares of Vivos Therapeutics in a research report on Wednesday, November 20th.

Hedge Funds Weigh In On Vivos Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in VVOS. Anson Funds Management LP bought a new position in shares of Vivos Therapeutics during the 4th quarter worth about $1,041,000. Cutter & CO Brokerage Inc. bought a new position in Vivos Therapeutics in the 4th quarter valued at about $163,000. Geode Capital Management LLC lifted its position in Vivos Therapeutics by 55.6% in the 4th quarter. Geode Capital Management LLC now owns 44,827 shares of the company’s stock valued at $192,000 after acquiring an additional 16,025 shares in the last quarter. Finally, Commonwealth Equity Services LLC lifted its position in Vivos Therapeutics by 23.8% in the 4th quarter. Commonwealth Equity Services LLC now owns 26,000 shares of the company’s stock valued at $112,000 after acquiring an additional 5,000 shares in the last quarter. Institutional investors own 26.35% of the company’s stock.

Vivos Therapeutics Price Performance

VVOS stock opened at $3.55 on Wednesday. The stock has a market capitalization of $20.91 million, a PE ratio of -0.62 and a beta of 7.47. The company’s 50-day moving average is $4.04 and its 200-day moving average is $3.57. Vivos Therapeutics has a 1 year low of $1.91 and a 1 year high of $6.28.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.